Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Liabilities and Shareholders Equity (2016 - 2025)

Apyx Medical's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $66.8 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 3.08% year-over-year to $66.8 million; the TTM value through Dec 2025 reached $242.6 million, down 7.31%, while the annual FY2025 figure was $66.8 million, 3.08% up from the prior year.
  • Liabilities and Shareholders Equity reached $66.8 million in Q4 2025 per APYX's latest filing, up from $57.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $79.2 million in Q4 2023 to a low of $51.8 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $63.4 million, with a median of $62.7 million recorded in 2022.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 24.66% in 2022, then skyrocketed 53.05% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $68.7 million in 2021, then fell by 24.66% to $51.8 million in 2022, then surged by 53.05% to $79.2 million in 2023, then decreased by 18.17% to $64.8 million in 2024, then grew by 3.08% to $66.8 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Liabilities and Shareholders Equity are $66.8 million (Q4 2025), $57.4 million (Q3 2025), and $58.2 million (Q2 2025).